1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Cellerino P, Corsi F, Morandi E, Foschi D
and Trabucchi E: Metastatic melanoma of the gallbladder. Eur J Surg
Oncol. 26:815–816. 2000. View Article : Google Scholar : PubMed/NCBI
|
3
|
Haskaraca MF, Ozsoy M, Ozsan I and Kurt K:
Primary malignant melanoma of the gallbladder: A case report and
review of the literature. Case Rep Surg. 2012:6935472012.PubMed/NCBI
|
4
|
Corrie P, Hategan M, Fife K and Parkinson
C: Management of melanoma. Br Med Bull. 111:149–162. 2014.
View Article : Google Scholar : PubMed/NCBI
|
5
|
Burki TK: Defining the genetics of
melanoma progression. Lancet Oncol. 17:e72016. View Article : Google Scholar : PubMed/NCBI
|
6
|
Zeng Y and Cullen BR: Sequence
requirements for micro RNA processing and function in human cells.
Rna. 9:112–123. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Li YC, Li CF, Chen LB, Li DD, Yang L, Jin
JP and Zhang B: MicroRNA-766 targeting regulation of SOX6
expression promoted cell proliferation of human colorectal cancer.
Onco Targets Ther. 8:2981–2988. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Cao J, Liu J, Xu R, Zhu X, Liu L and Zhao
X: MicroRNA-21 stimulates epithelial-to-mesenchymal transition and
tumorigenesis in clear cell renal cells. Mol Med Rep. 13:75–82.
2016. View Article : Google Scholar : PubMed/NCBI
|
10
|
Puglisi F, Minisini AM, De Angelis C and
Arpino G: Overcoming treatment resistance in HER2-positive breast
cancer: Potential strategies. Drugs. 72:1175–1193. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Bennett PE, Bemis L, Norris DA and
Shellman YG: miR in melanoma development: miRNAs and acquired
hallmarks of cancer in melanoma. Physiol Genomics. 45:1049–1059.
2013. View Article : Google Scholar : PubMed/NCBI
|
12
|
da Cruz AT and Jasiulionis MG: miRNAs and
melanoma: How are they connected? Dermatol Res Pract.
2012:5283452012.PubMed/NCBI
|
13
|
Mannavola F, Tucci M, Felici C, Stucci S
and Silvestris F: miRNAs in melanoma: A defined role in tumor
progression and metastasis. Expert Rev Clin Immunol. 12:79–89.
2016. View Article : Google Scholar : PubMed/NCBI
|
14
|
Mueller DW, Rehli M and Bosserhoff AK:
miRNA expression profiling in melanocytes and melanoma cell lines
reveals miRNAs associated with formation and progression of
malignant melanoma. J Invest Dermatol. 129:1740–1751. 2009.
View Article : Google Scholar : PubMed/NCBI
|
15
|
Bertorello AM and Zhu JK: SIK1/SOS2
networks: Decoding sodium signals via calcium-responsive protein
kinase pathways. Pflugers Arch. 458:613–619. 2009. View Article : Google Scholar : PubMed/NCBI
|
16
|
Lee J, Tong T, Takemori H and Jefcoate C:
Stimulation of StAR expression by cAMP is controlled by inhibition
of highly inducible SIK1 via CRTC2, a co-activator of CREB. Mol
Cell Endocrinol. 408:80–89. 2015. View Article : Google Scholar : PubMed/NCBI
|
17
|
Cheng H, Liu P, Wang ZC, Zou L, Santiago
S, Garbitt V, Gjoerup OV, Iglehart JD, Miron A, Richardson AL, et
al: SIK1 couples LKB1 to p53-dependent anoikis and suppresses
metastasis. Sci Signal. 2:ra352009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Yao YH, Cui Y, Qiu XN, Zhang LZ, Zhang W,
Li H and Yu JM: Attenuated LKB1-SIK1 signaling promotes
epithelial-mesenchymal transition and radioresistance of non-small
cell lung cancer cells. Chin J Cancer. 35:502016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Selvik LK, Rao S, Steigedal TS, Haltbakk
I, Misund K, Bruland T, Prestvik WS, Lægreid A and Thommesen L:
Salt-inducible kinase 1 (SIK1) is induced by gastrin and inhibits
migration of gastric adenocarcinoma cells. PLoS One. 9:e1124852014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Zhai W, Sun Y, Jiang M, Wang M, Gasiewicz
TA, Zheng J and Chang C: Differential regulation of LncRNA-SARCC
suppresses VHL-mutant RCC cell proliferation yet promotes
VHL-normal RCC cell proliferation via modulating androgen
receptor/HIF-2α/C-MYC axis under hypoxia. Oncogene. 35:4866–4880.
2016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Wei F, Cao C, Xu X and Wang J: Diverse
functions of miR-373 in cancer. J Transl Med. 13:1622015.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Wei F, Wang Q, Su Q, Huang H, Luan J, Xu X
and Wang J: miR-373 inhibits glioma cell U251 migration and
invasion by down-regulating CD44 and TGFBR2. Cell Mol Neurobiol.
36:1389–1397. 2016. View Article : Google Scholar : PubMed/NCBI
|
24
|
Zhang Y, Zhao FJ, Chen LL, Wang LQ, Nephew
KP, Wu YL and Zhang S: MiR-373 targeting of the Rab22a oncogene
suppresses tumor invasion and metastasis in ovarian cancer.
Oncotarget. 5:12291–12303. 2014.PubMed/NCBI
|
25
|
Eyking A, Reis H, Frank M, Gerken G,
Schmid KW and Cario E: MiR-205 and MiR-373 are associated with
aggressive human mucinous colorectal cancer. PLoS One.
11:e01568712016. View Article : Google Scholar : PubMed/NCBI
|
26
|
Ding W, Fan XL, Xu X, Huang JZ, Xu SH,
Geng Q, Li R, Chen D and Yan GR: Epigenetic silencing of ITGA2 by
MiR-373 promotes cell migration in breast cancer. PLoS One.
10:e01351282015. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chen D, Dang BL, Huang JZ, Chen M, Wu D,
Xu ML, Li R and Yan GR: MiR-373 drives the
epithelial-to-mesenchymal transition and metastasis via the
miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer.
Oncotarget. 6:32701–32712. 2015.PubMed/NCBI
|
28
|
Qu C, He D, Lu X, Dong L, Zhu Y, Zhao Q,
Jiang X, Chang P, Jiang X, Wang L, et al: Salt-inducible kinase
(SIK1) regulates HCC progression and WNT/β-catenin activation. J
Hepatol. 64:1076–1089. 2016. View Article : Google Scholar : PubMed/NCBI
|
29
|
Ren ZG, Dong SX, Han P and Qi J: miR-203
promotes proliferation, migration and invasion by degrading SIK1 in
pancreatic cancer. Oncol Rep. 35:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI
|
30
|
Chen JL, Chen F, Zhang TT and Liu NF:
Suppression of SIK1 by miR-141 in human ovarian cancer cell lines
and tissues. Int J Mol Med. 37:1601–1610. 2016. View Article : Google Scholar : PubMed/NCBI
|